NICE guidance on omalizumab for severe asthma.

The lancet. Respiratory medicine

Volumn 1, Issue 3, 2013, Pages 189-190

  Diaz, Richard A ^a   Charles, Zoe ^a   George, Elisabeth ^a   Adler, Amanda I ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADOLESCENT; ADULT; ASTHMA; CHILD; DRUG APPROVAL; DRUG COST; ECONOMICS; HUMAN; NOTE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RESPIRATORY TRACT ALLERGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DRUG APPROVAL; DRUG COSTS; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY HYPERSENSITIVITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84894575078     PISSN: 22132600     EISSN: None     Source Type: None    
DOI: 10.1016/S2213-2600(13)70066-3     Document Type: Note

References (0)